GSK gives up fight to protect patent in China

08/18/2004 | Guardian (London), The

GlaxoSmithKline reportedly has abandoned a court fight in China to protect its patent on the diabetes drug, Avandia, apparently fearing it had little chance of winning. GSK holds the basic patent for Avandia, but Chinese generic firms have challenged patents for different doses and versions of the drug, known as "salts." The move follows China's decision to strip Pfizer's Viagra patent in the country, an action roundly condemned by foreign pharmaceutical firms that hope to remain in China's growing market for drugs.

View Full Article in:

Guardian (London), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY